Emergency department presentations, hospitalisations and police seizure data related to gamma‐hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024
Addiction · 2026
DOI: 10.1111/add.70202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Addiction, 2026. Verfasst von Krista J Siefried und 9 weiteren Autor:innen. Beteiligte Einrichtung: The National Centre for Clinical Research on Emerging Drugs (NCCRED), the University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Sodium Oxybate, Emergency Service, Hospital, Hospitalization, Police. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and aims Gamma‐hydroxybutyrate (GHB) is an endogenous neurochemical and illicit synthetic drug. Its precursors, gamma‐butyrolactone (GBL) and 1,4‐butanediol (1,4‐BD), are often used as substitutes. We aimed to describe GHB‐related harms in New South Wales (NSW), Australia. Design, setting and cases Descriptive epidemiological study of data from three administrative datasets: emergency department (ED) presentations from 88 hospitals (1 July 2015 to 31 January 2024 – the latest available), admitted patient data from all NSW hospitals (1 July 2015 to 30 June 2023) and a subset of NSW Police Force seizure data. Note: analysis was not undertaken, data are presented descriptively.
Measurements
ED presentations and hospitalisations were analysed for GHB‐related presentations and admissions including severity of presentation, intubation and intensive care. NSW Police Force seizure data were examined for all analytically confirmed samples of GHB, GBL and 1,4‐BD to assess trends over time.
Findings
Over the study period, there were 9612 GHB‐related ED presentations. Between July 2023 and January 2024, this was 101 per 100 000 unplanned presentations, relative to the previous full‐year peak of 73.7 per 100 000 in 2022–2023 and the 2015–2016 rate of 24.9 per 100 000. The majority (56.1%) were assessed as Australian Triage Category 1 or 2, indicating the highest level of need. ED presentations in regional or remote areas accounted for 13.8% of all presentations in the most recent data, relative to 3.4% at the start of the study period. Hospitalisations totalled 6420 episodes, peaking at 19.6 per 100 000 population in 2020–2021. Nearly one in five patients required intubation, and a similar proportion required admission to intensive care. There was a trend of women accounting for a larger proportion of ED presentations and hospitalisations over time. GHB accounted for 0.1% of all police seizures analysed, and showed a shift from GBL to 1,4‐BD dominance from 2022 onwards.
Conclusions
Gamma‐hydroxybutyrate‐related emergency department presentations and hospitalisations in New South Wales, Australia, appear to have increased over the period from 2015 to 2024, which can support public health campaigns to reduce gamma‐hydroxybutyrate‐related harms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The National Centre for Clinical Research on Emerging Drugs (NCCRED), the University of New South Wales, Sydney, Australia.
- Alcohol and Drug Service, St Vincent's Hospital Sydney, Darlinghurst, Australia.
- The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia.
- New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), c/o New South Wales Ministry of Health, St Leonards, Australia.
- Centre for Alcohol and Other Drugs, New South Wales Ministry of Health, St Leonards, Australia.
- ACON, Sydney, Australia.
ORCID-Profile: Krista J Siefried, Janette L Smith, Christine A Harvey, Anthony Nedanoski, Jared A Brown, Una Cullinan, Nadine Ezard, Thanjira Jiranantakan, Darren M Roberts, Jonathan Brett
Zitieren
APA
Siefried, K. J., Smith, J. L., Harvey, C. A., Nedanoski, A., Brown, J. A., Cullinan, U., Ezard, N., Jiranantakan, T., Roberts, D. M., & Brett, J. (2026). Emergency department presentations, hospitalisations and police seizure data related to gamma‐hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024. Addiction. https://doi.org/10.1111/add.70202
Vancouver
Siefried KJ, Smith JL, Harvey CA, Nedanoski A, Brown JA, Cullinan U, et al. Emergency department presentations, hospitalisations and police seizure data related to gamma‐hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024. Addiction. 2026. doi:10.1111/add.70202
BibTeX
@article{Siefried2026,
author = {Siefried, Krista J and Smith, Janette L and Harvey, Christine A and Nedanoski, Anthony and Brown, Jared A and Cullinan, Una and Ezard, Nadine and Jiranantakan, Thanjira and Roberts, Darren M and Brett, Jonathan},
title = {Emergency department presentations, hospitalisations and police seizure data related to gamma‐hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024},
journal = {Addiction},
year = {2026},
doi = {10.1111/add.70202}
}
EUVIMED